![]() ![]() Novamind’s investment in Synthesis and its acquisition (pending) of Cedar Psychiatry provides Novamind with access to proprietary resources including psychedelic-assisted psychotherapy protocols, industry-leading data, patient screening tools, leading facilitators and scientific advisors. The purchase price for the Cedar Psychiatry acquisition is $3,050,000 consisting of 5,125,000 Novamind Consolidated Shares (as defined below) to be issued at a deemed price of $0.40 per share and cash payments totalling $1,000,000 to be paid over 12 months from closing of the Cedar Acquisition. Novamind’s acquisition of Cedar Psychiatry is expected to close prior to the Qualifying Transaction. Cedar Psychiatry operates three psychiatry clinics specialized in ketamine-assisted psychotherapy, and a dedicated research center that conducts novel clinical trials. a letter of intent to purchase 100% of the assets of Cedar Psychiatry LLC and Cedar Clinical Research LLC (“ Cedar Psychiatry”), a leading provider of psychedelic-assisted psychotherapy and research, based in the United States (the “Cedar Acquisition”).The investment in Synthesis was funded in cash and closed in multiple tranches beginning in November 2019 with the final tranche completed in March 2020 and (“ Synthesis”), a Netherlands-based psychedelics retreat offering an interdisciplinary approach to safe, legal psilocybin experiences. With this as a prerequisite, Novamind was an early mover in 2019 and made two strategic investments in industry-leading psychedelic retreats and clinics: ![]() Until such time that the FDA approves new psychedelic medicines, Novamind invests and operates exclusively in those jurisdictions with established legal regulations for the use of psychedelics. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry. Food and Drug Administration (“FDA”) are currently evaluating the safety and efficacy of MDMA-assisted psychotherapy (to treat PTSD) and psilocybin-assisted psychotherapy (to treat depression), and if approved, will require specialized infrastructure to facilitate patient treatment. Ongoing clinical trials approved by the U.S. Novamind was founded in May 2019 in Toronto, Canada. Novamind invests in the infrastructure that drives the world’s leading psychedelic clinics and retreats. Upon completion of the Qualifying Transaction and the Financing (as defined and described below), it is expected that Buzz Capital (following the Qualifying Transaction, the “ Resulting Issuer”) will be a Tier 2 Industrial Issuer, subject to Exchange approval. The proposed transaction is intended to constitute an arm’s length qualifying transaction (the " Qualifying Transaction") for Buzz Capital, as defined in Policy 2.4 of the Exchange. ![]() (TSXV: BUZ.P) (" Buzz Capital" or the " Corporation"), a capital pool company listed on the TSX Venture Exchange (the " Exchange"), is pleased to announce that it has signed a letter of intent dated (the " Letter of Intent") with Novamind Ventures Inc., an Ontario corporation, (" Novamind”) to complete a business combination by way of a transaction that will constitute a reverse takeover of Buzz Capital by Novamind. TORONTO, (GLOBE NEWSWIRE) - Buzz Capital Inc. Any failure to comply with this restriction may constitute a violation of U.S. Newswire Services or for dissemination in the United States. ![]()
0 Comments
Leave a Reply. |